The biotechnology industry is a vibrant community of researchers, business executives, and investors often charting new territory in the pursuit of innovation. After many years of investing in both public and private companies across the therapeutic, diagnostic, and device landscapes, our team has come to recognize some of the patterns of success and failure. We believe in openly contributing what we know; we have shared our perspective on valuation methods, business models, clinical trial design, and other best practices gleaned from hundreds of case studies in boardrooms, classrooms, conferences, and articles.
For example, we have helped entrepreneurs identify comparables for their businesses, guided management teams in prioritizing their development programs, helped companies gauge when they might be IPO-ready, and informed companies’ decision about how much capital to raise, when to raise it, which banks to work with, and which investors to talk to.
On occasion, we have also had the pleasure of speaking with students near and far (University of Helsinki currently holds the record/tops the charts/is the current leader for furthest distance). We typically discuss trends in innovation, how we invest, and risks in the healthcare and life science industries; we hope they remember us when they someday launch companies and are looking for capital.
We do our best to make time for outreach and welcome all queries –
contact Katie Maher at firstname.lastname@example.org.